Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Nash

Showing results (51-60 of 198) with videos related to

Pageof 20
Sort By:
Arthritis Research & Therapy|January 4, 2022
The impact of filgotinib on patient-reported outcomes and health-related quality of life for patients with active rheumatoid arthritis: a post hoc analysis of Phase 3 studiesClifton O Bingham, David Walker, Peter Nash, et al.
Annals of the Rheumatic Diseases|January 19, 2018
Early and sustained efficacy with apremilast monotherapy in biological-naïve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE)Peter Nash, Kamal Ohson, Jessica Walsh, et al.
BMJ Open|November 8, 2023
Systematic literature review and network meta-analysis of therapies for psoriatic arthritis on patient-reported outcomesPeter Nash, Jan P Dutz, Steve Peterson, et al.
European Journal of Rheumatology|August 1, 2019
Comparative effectiveness of secukinumab and etanercept in biologic-naïve patients with psoriatic arthritis assessed by matching-adjusted indirect comparisonPhilip Mease, Ernest Choy, Peter Nash, et al.
Rheumatology and Therapy|June 28, 2018
Tofacitinib, an Oral Janus Kinase Inhibitor: Pooled Efficacy and Safety Analyses in an Australian Rheumatoid Arthritis PopulationStephen Hall, Peter Nash, Maureen Rischmueller, et al.
The Journal of Rheumatology|June 2, 2024
Efficacy and Safety of Tofacitinib in Ankylosing Spondylitis by Baseline C-Reactive Protein Level: Post Hoc Analysis of Phase II and Phase III Clinical TrialsAtul Deodhar, Xenofon Baraliakos, Marina Magrey, et al.
Clinical Rheumatology|June 8, 2022
Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year resultsLaura C Coates, Philip Mease, Andris Kronbergs, et al.
Clinical Rheumatology|July 12, 2022
Correction to: Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year resultsLaura C Coates, Philip Mease, Andris Kronbergs, et al.
Clinical Rheumatology|November 8, 2014
Rheumatoid arthritis in the Middle East and Africa: are we any closer to optimising its management?Jamal Al Saleh, Gaafar Ragab, Peter Nash, et al.
Rheumatology and Therapy|August 9, 2024
Comparative Effectiveness of Bimekizumab and Ustekinumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect ComparisonPhilip J Mease, Richard B Warren, Peter Nash, et al.
Pageof 20

Showing results (51-60 of 198) with videos related to

Sort By:
Pageof 20
Arthritis Research & Therapy|January 4, 2022
The impact of filgotinib on patient-reported outcomes and health-related quality of life for patients with active rheumatoid arthritis: a post hoc analysis of Phase 3 studiesClifton O Bingham, David Walker, Peter Nash, et al.
Annals of the Rheumatic Diseases|January 19, 2018
Early and sustained efficacy with apremilast monotherapy in biological-naïve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE)Peter Nash, Kamal Ohson, Jessica Walsh, et al.
BMJ Open|November 8, 2023
Systematic literature review and network meta-analysis of therapies for psoriatic arthritis on patient-reported outcomesPeter Nash, Jan P Dutz, Steve Peterson, et al.
European Journal of Rheumatology|August 1, 2019
Comparative effectiveness of secukinumab and etanercept in biologic-naïve patients with psoriatic arthritis assessed by matching-adjusted indirect comparisonPhilip Mease, Ernest Choy, Peter Nash, et al.
Rheumatology and Therapy|June 28, 2018
Tofacitinib, an Oral Janus Kinase Inhibitor: Pooled Efficacy and Safety Analyses in an Australian Rheumatoid Arthritis PopulationStephen Hall, Peter Nash, Maureen Rischmueller, et al.
The Journal of Rheumatology|June 2, 2024
Efficacy and Safety of Tofacitinib in Ankylosing Spondylitis by Baseline C-Reactive Protein Level: Post Hoc Analysis of Phase II and Phase III Clinical TrialsAtul Deodhar, Xenofon Baraliakos, Marina Magrey, et al.
Clinical Rheumatology|June 8, 2022
Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year resultsLaura C Coates, Philip Mease, Andris Kronbergs, et al.
Clinical Rheumatology|July 12, 2022
Correction to: Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year resultsLaura C Coates, Philip Mease, Andris Kronbergs, et al.
Clinical Rheumatology|November 8, 2014
Rheumatoid arthritis in the Middle East and Africa: are we any closer to optimising its management?Jamal Al Saleh, Gaafar Ragab, Peter Nash, et al.
Rheumatology and Therapy|August 9, 2024
Comparative Effectiveness of Bimekizumab and Ustekinumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect ComparisonPhilip J Mease, Richard B Warren, Peter Nash, et al.
Pageof 20